时间延迟：探寻阿尔茨海默病疾病修饰的有意义结果：2023年欧洲药物经济学与结果研究协会（ISPOR）教育研讨会报告 - Suppr

Suppr

超能文献

Time Delay: Searching for a Meaningful Outcome of Disease Modification in Alzheimer Disease: A Report of the Educational Symposium Held at ISPOR Europe 2023.

作者信息

Schiel Anja, Brogaard Niels Juul, Hahn-Pedersen Julie, Schlueter Max, Jönsson Linus

机构信息

Norwegian Medical Products Agency (NOMA), Oslo, Norway.

Novo Nordisk A/S, Bagsværd, Denmark.

出版信息

Alzheimer Dis Assoc Disord. 2025;39(1):60-63. doi: 10.1097/WAD.0000000000000654. Epub 2025 Jan 10.

DOI:10.1097/WAD.0000000000000654

PMID:39790094

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11841714/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10b9/11841714/0a7f5344df54/wad-39-60-g001.jpg

相似文献

Time Delay: Searching for a Meaningful Outcome of Disease Modification in Alzheimer Disease: A Report of the Educational Symposium Held at ISPOR Europe 2023.时间延迟：探寻阿尔茨海默病疾病修饰的有意义结果：2023年欧洲药物经济学与结果研究协会（ISPOR）教育研讨会报告

Alzheimer Dis Assoc Disord. 2025;39(1):60-63. doi: 10.1097/WAD.0000000000000654. Epub 2025 Jan 10.

The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.ISPOR 成本效益研究质量改进良好实践工作组报告。

Value Health. 2009 Nov-Dec;12(8):1086-99. doi: 10.1111/j.1524-4733.2009.00605.x. Epub 2009 Sep 10.

Alzheimer's disease: a report from the 7th Kuopio Alzheimer symposium.阿尔茨海默病：第七届库奥皮奥阿尔茨海默病研讨会报告

Neurodegener Dis Manag. 2015 Oct;5(5):379-82. doi: 10.2217/nmt.15.31. Epub 2015 Oct 19.

ISPOR Code of Ethics for Researchers background article--report of the ISPOR Task Force on Code of Ethics for Researchers.药物经济学与结果研究国际协会（ISPOR）研究人员伦理准则背景文章——ISPOR研究人员伦理准则特别工作组报告

Value Health. 2004 Mar-Apr;7(2):111-7. doi: 10.1111/j.1524-4733.2004.72366.x.

Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force.构建离散选择实验的实验设计：ISPOR 联合分析实验设计良好实践工作组报告。

Value Health. 2013 Jan-Feb;16(1):3-13. doi: 10.1016/j.jval.2012.08.2223.

Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.关于支持电子和纸质患者报告结局（PRO）测量等效性所需证据的建议：国际药物经济学与结果研究协会（ISPOR）电子PRO良好研究实践工作组报告

Value Health. 2009 Jun;12(4):419-29. doi: 10.1111/j.1524-4733.2008.00470.x. Epub 2008 Nov 11.

Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.药物成本测量在成本效果分析中的良好研究实践：问题与建议：ISPOR 药物成本工作组报告——第一部分。

Value Health. 2010 Jan-Feb;13(1):3-7. doi: 10.1111/j.1524-4733.2009.00663.x. Epub 2009 Oct 28.

A Technical Review of the ISPOR Presentations Database Identified Issues in the Search Interface and Areas for Future Development.ISPOR 演示文稿数据库的技术审查发现了搜索界面中的问题和未来发展领域。

Int J Technol Assess Health Care. 2022 Mar 8;38(1):e29. doi: 10.1017/S0266462322000137.

Towards an earlier diagnosis of Alzheimer disease (Proceedings of the 5th MCI Symposium, 2007).迈向阿尔茨海默病的早期诊断（第五届轻度认知障碍研讨会会议记录，2007年）

Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):99-110. doi: 10.1097/WAD.0b013e3181630b93.

A report from the 8th Kuopio Alzheimer Symposium.第八届库奥皮奥阿尔茨海默病研讨会报告。

Neurodegener Dis Manag. 2018 Oct;8(5):289-299. doi: 10.2217/nmt-2018-0029. Epub 2018 Aug 16.

本文引用的文献

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease.进展分析与传统方法定量阿尔茨海默病疾病进展减缓的比较。

Alzheimers Res Ther. 2024 Feb 29;16(1):48. doi: 10.1186/s13195-024-01413-y.

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。

JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.

Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab

N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.

Progression models for repeated measures: Estimating novel treatment effects in progressive diseases.重复测量的进展模型：在进行性疾病中估计新的治疗效果。

Stat Med. 2022 Dec 10;41(28):5537-5557. doi: 10.1002/sim.9581. Epub 2022 Sep 17.

What Matters to Patients with Alzheimer's Disease and Their Care Partners? Implications for Understanding the Value of Future Interventions.对阿尔茨海默病患者及其护理伙伴重要的是什么？对理解未来干预措施价值的启示。

J Prev Alzheimers Dis. 2022;9(3):550-555. doi: 10.14283/jpad.2022.22.

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.阿尔茨海默病早期临床试验终点及其临床意义。

J Prev Alzheimers Dis. 2022;9(3):507-522. doi: 10.14283/jpad.2022.41.

Dose-Response Mixed Models for Repeated Measures - a New Method for Assessment of Dose-Response.剂量反应混合模型在重复测量中的应用——一种评估剂量反应的新方法。

Pharm Res. 2020 Jul 31;37(8):157. doi: 10.1007/s11095-020-02882-0.

Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes.评估患有或有阿尔茨海默病风险的患者及其护理伙伴最关心的问题：一项评估症状、影响和结果的定性研究。

Alzheimers Res Ther. 2020 Jul 30;12(1):90. doi: 10.1186/s13195-020-00659-6.

Early Detection of Mild Cognitive Impairment (MCI) in Primary Care.在初级保健中早期发现轻度认知障碍（MCI）。

J Prev Alzheimers Dis. 2020;7(3):165-170. doi: 10.14283/jpad.2020.21.

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials.阿尔茨海默病临床试验临床结局评估中的疾病严重程度及最小临床重要差异

Alzheimers Dement (N Y). 2019 Aug 2;5:354-363. doi: 10.1016/j.trci.2019.06.005. eCollection 2019.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验